Dr Michelle Li is an early-career clinician researcher with a demonstrated strong interest in breast cancer.
Her research was presented as an abstract at the San Antonio Breast Cancer Symposium in
2023, which was a real-world retrospective study characterising the incidence of HER2-low in
metastatic breast cancer patients at a metropolitan cancer center in Melbourne, Australia.

Following this, she was accepted into a competitive Clinical Trials and Translational Research
Fellowship at the Peter MacCallum Cancer Centre and has spent this year working under the
mentorship of Professor Sherene Loi.

She is currently the sub-investigator on all clinical trials in the breast trials portfolio, which includes both early and late-phase studies across all breast
cancer subtypes and stages of disease. Many of these trials are sponsored by Breast Cancer Trials, including
OPTIMA, OLIO, CAPTURE, and TUGETHER.

Her involvement has included the active recruitment of
trial participants, documentation of trial reviews, interpretation of trial protocols and
appropriate management of trial-related adverse events.